ArticleCancer diagnosis & prognosis
Usefulness of White Blood Cell Differential-based Indices in Patients With Extensive-stage Small Cell Lung Cancer.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Indices based on the white blood cell (WBC) count and WBC differential count are simple and can be easily calculated using routine blood tests. Many studies have examined the usefulness of these indices for predicting prognosis for various cancers, including lung cancer. However, no studies have focused on the relationships between indices based solely on WBC and WBC differential counts and the prognosis of patients with extensive-stage small cell lung cancer (ES-SCLC). The aim of this study was to evaluate the prognostic value of indices based on WBC and WBC differential counts in patients with ES-SCLC treated with platinum-doublet chemotherapy. Patients and Methods: The pretreatment neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), neutrophil-to-monocyte ratio (NMR), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-WBC ratio (NWR), lymphocyte-to-WBC ratio (LWR), monocyte-to-WBC ratio (MWR), neutrophil-to-eosinophil ratio (NER), lymphocyte-to-eosinophil ratio (LER), monocyte-to-eosinophil ratio (MER), eosinophil*neutrophil-to-lymphocyte ratio (ENLR), systemic inflammation response index (SIRI), and inflammatory related ratio (IRR) of patients with ES-SCLC who were treated with platinum-doublet chemotherapy as first-line treatment at Kainan Hospital were retrospectively analyzed. Results: Data from 102 patients were analyzed. On multivariate analysis, patients with low MLR, MWR, NER, MER, and IRR values had significantly longer overall survival (OS) than patients with high MLR, MWR, NER, MER, and IRR values. In addition, patients with low WBC and monocyte counts had significantly longer OS than patients with high WBC and monocyte counts. Conclusion: Indices based on WBC and WBC differential counts, especially monocyte-related indices, may be useful markers for predicting the prognosis of patients with ES-SCLC treated with platinum-doublet chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.